Asenapine (USAN, rINNM and BANM; trade names Saphris (AU, US, RU), Sycrest (EU, UK)) is an atypical antipsychotic developed for the treatment of schizophrenia and acute mania associated with bipolar disorder by Schering-Plough after its November 19, 2007 merger with Organon International. Development of the drug, through Phase III trials, began while Organon was still a part of Akzo Nobel. Preliminary data indicate that it has minimal anticholinergic and cardiovascular side effects, as well as minimal weight gain. Over 3000 patients have participated in clinical trials of asenapine, and the FDA approved the manufacturer's NDA in August 2009.

CAS：65576-45-6
中文别名：反式-5-氯-2,3,3A,12B-四氢-2-甲基-1H-二苯并[2,3:6,7]氧杂卓并[4,5-C]吡咯;马来酸阿莫沙平;
英文别名：trans-5-Chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenz<2,3:6,7>oxepino<4,5-c>pyrrolidine;scorbicpalmitate;Vitamin C Palmitate;L-Ascorbic Acid 6-Palmitate;6-palmitoylascorbic acid;<36Cl>-trans-5-chloro-2,3,3a,12b-tetrahydro-2-methyl-1H-dibenz<2,3:6,7>oxepino<4,5-c>pyrrole;
分子式：C17H16ClNO
分子量：285.768
精确质量：285.092
Psa：12.47
Logp：4.1964

EINECS号：265-829-4

密度：1.231
沸点：357.9ºC at 760 mmHg
闪点：170.2ºC
折射率：1.609

海关编码：2934999090